This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Greater Manchester practice randomises first UK patient to flu virus study

A Greater Manchester primary care centre has randomised the first UK patient of the winter season on to a flu virus study.

The patient was placed on to the DIAMOND study at Barlow Medical Centre in Didsbury, where Dr Allcock is Principal Investigator.

The placebo-controlled study is being delivered at five centres in GM. It is looking at the use of the medication Pimodivir in combination with the standard-of-care treatment in adolescent, adult, and elderly people with Influenza A Infection.

The Phase 3 study is sponsored by Janssen in collaboration with the Clinical Research Organisation (CRO) IQVIA.

Anna-Liisa Parts, IQVIA Associate Clinical Lead for Site Management, said: “I wanted to really thank Dr Allcock and his team for this wonderful achievement and hard work on the study.

“Dr Allcock and his team were successful in randomizing the first patient in the UK. I wish them all the best in their work and in the future screenings and randomizations.”